JSR Life Sciences, the life-sciences focused division of JSR Corporation, will offer industry partners best-in-class CDMO services by complementing its commercial subsidiary KBI Biopharma with Selexis SA Technologies
JSR Life Sciences (JLS) announced today that JSR Corporation has agreed to acquire Selexis SA, a pioneering life sciences company and global leader in mammalian (suspension-adapted CHO-K1) cell-line generation technologies. Once completed, this transaction will mark the second major biotechnology addition to the JSR group of companies following JSR Corporation’s acquisition of KBI Biopharma in 2015. Selexis will be integrated within KBI Biopharma’s operations to create the most robust and fastest “Gene to GMP” service offering in the biopharmaceutical industry.
With biopharma’s ever-evolving pipeline of novel protein therapeutics, such as bi-specific antibodies, multimeric proteins and Fc-fusion proteins, CHO cells are being pushed to their productivity limits in drug development and manufacturing. Biopharmaceutical companies working on these promising new therapies are increasingly struggling with development challenges such as weak protein expression, low-yield purification steps, and poorly optimized analytical techniques. Without addressing these challenges, many of these new medicines capable of treating serious, intractable diseases would never advance out of the pre-clinical phase. Selexis has made its mark with its SUREtechnology Platform™ that facilitates the rapid, stable, and cost-effective generation of cell lines producing virtually any recombinant protein. KBI has a proven track record of delivering therapeutic candidates into the clinic by leveraging its strengths in process development and analytics. Moreover, KBI and Selexis already have a long history of successful collaboration on behalf of their partners, as KBI has performed development and/or manufacturing services using more than 15 different Selexis generated cell lines since 2012.